ArticleJournal of Alzheimer's disease : JAD2017
Detecting At-Risk Alzheimer's Disease Cases.
Article in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- APOE in subjective cognitive decline: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- Cognitive Functioning of Unaffected First-degree Relatives of Individuals With Late-onset Alzheimer's Disease: A Systematic Literature Review and Meta-analysis.Neuropsychology review · 2023Pooled it
- Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.Acta neuropathologica · 2022Pooled it
- The Cognitive Profile of Mild Cognitive Impairment Due to Dementia With Lewy Bodies-An Updated Review.Frontiers in aging neuroscience · 2020Pooled it
- Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk loci.Scientific reports · 2018Pooled it
- Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression.Scientific reports · 2021Trial
- Interpreting p-tau217 on the ward: frailty and plasma biomarkers in acutely admitted older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Cerebrospinal fluid NPTX1 and NPTXR predict neurodegeneration and clinical progression in Alzheimer's disease.Nature communications · 2026Article
- Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer's disease genetic pathways.Molecular neurodegeneration · 2025Article
- Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease.Neurology · 2025Observational
- Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting.Journal of Alzheimer's disease : JAD · 2025Article
- Mild cognitive impairment and neuropsychological examination.Frontiers in psychology · 2025Review
- The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer's disease.Brain communications · 2025Article
- Sexual dimorphisms in innate immune activation markers in predementia Alzheimer's disease.Brain communications · 2025Article
- Regression-based normative data for the D-KEFS Color-Word Interference Test in Norwegian adults ages 20-85.The Clinical neuropsychologist · 2024Article
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease.Nature communications · 2024Article
- Plasma phosphorylated-tau217 is increased in Niemann-Pick disease type C.Brain communications · 2024Article
- Early detection of mild cognitive impairment through neuropsychological tests in population screenings: a decision support system integrating ontologies and machine learning.Frontiers in neuroinformatics · 2024Article
- Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer's disease cohorts.Frontiers in aging neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While APOEɛ4 is the major genetic risk factor for Alzheimer's disease (AD), amyloid dysmetabolism is an initial or early event predicting clinical disease and is an important focus for secondary intervention trials. To improve identification of cases with increased AD risk, we evaluated recruitment procedures using pathological CSF concentrations of Aβ42 (pAβ) and APOEɛ4 as risk markers in a multi-center study in Norway. In total, 490 subjects aged 40-80 y were included after response to advertisements and media coverage or memory clinics referrals. Controls (n = 164) were classified as normal controls without first-degree relatives with dementia (NC), normal controls with first-degree relatives with dementia (NCFD), or controls scoring below norms on cognitive screening. Patients (n = 301) were classified as subjective cognitive decline or mild cognitive impairment. Subjects underwent a clinical and cognitive examination and MRI according to standardized protocols. Core biomarkers in CSF from 411 and APOE genotype from 445 subjects were obtained. Cases (both self-referrals (n = 180) and memory clinics referrals (n = 87)) had increased fractions of pAβ and APOEɛ4 frequency compared to NC. Also, NCFD had higher APOEɛ4 frequencies without increased fraction of pAβ compared to NC, and cases recruited from memory clinics had higher fractions of pAβ and APOEɛ4 frequency than self-referred. This study shows that memory clinic referrals are pAβ enriched, whereas self-referred and NCFD cases more frequently are pAβ negative but at risk (APOEɛ4 positive), suitable for primary intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.